Plasma cell leukemia: concepts and management

References

• Ramsingh G, Mehan P, Luo J, Vij R, Morgensztern D. Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004. Cancer115(24), 5734–5739 (2009).
   PubMed Web of Science ®Google Scholar
• Tiedemann RE, Gonzalez-Paz N, Kyle RA et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia22, 1044–1052 (2008).
   PubMed Web of Science ®Google Scholar
• Jimenez-Zepeda VH, Dominguez-Martinez VJ. Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis. Int. J. Hematol.89, 259–268 (2009).
   PubMed Web of Science ®Google Scholar
• Garcıa-Sanz R, Orfao A, Gonzalez M et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood93(3), 1032–1037 (1999).
   PubMed Web of Science ®Google Scholar
• Blade J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma and plasma cell leukemia. Hematol. Oncol. Clin. North Am.13, 1259–1272 (1999).
   PubMed Web of Science ®Google Scholar
• Mckenna RW, Kyle RA, Kuehl WM et al. Plasma cell neoplasms. In: World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL et al. (Eds). IARC Press, Lyon, France 200–213 (2008).
   Google Scholar
• Pellat-Deceunynck C, Barille S, Jego G et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia12(12), 1977–1982 (1998).
   PubMed Web of Science ®Google Scholar
• Kraj M, Kopeć-Szlęzak J, Pogłód R, Kruk B. Flow cytometric immunophenotypic characteristics of 36 cases of plasma cell leukemia. Leuk. Res. DOI: 10.1016/j.leukres.2010.04.021 (2010) (Epub ahead of print).
   Google Scholar
• Avet-Loiseau H, Daviet A, Brigaudeau C et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique Hématologique. Blood97(3), 822–825 (2001).
   PubMed Web of Science ®Google Scholar
• Fonseca R, Van Wier SA, Chng WJ et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia20, 2034–2040 (2006).
   PubMed Web of Science ®Google Scholar
• Vela-Ojeda J, Garcia-Ruiz Esparza MA, Rosas-Cabral A et al. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia. Ann. Hematol.81(7), 362–367 (2002).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Palumbo A, Delasalle KB et al. Primary plasma cell leukaemia. Br. J. Haematol.88(4), 754–759 (1994).
   PubMed Web of Science ®Google Scholar
• Murthy V, Mwirigi A, Ward S, Rassam SMB. Rapid and excellent response to hyperCVAD, particularly with thalidomide, in plasma cell leukaemia and long term remissions following allogeneic stem cell transplantation. Presented at: American Society of Hematology 51st Annual Meeting. New Orleans, LA, USA, 5–8 December 2009.
   Google Scholar
• Saccaro S, Fonseca R, Veillon DM et al. Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am. J. Hematol.78(4), 288–294 (2005).
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim J, Cho Y et al. Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia. Jpn. J. Clin. Oncol.37(5), 382–384 (2007).
   PubMed Web of Science ®Google Scholar
• Grassinger J, Sudhoff T, Andreesen R, Hennemann B. Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib. Ann. Hematol.85(2), 132–133 (2006).
   PubMed Web of Science ®Google Scholar
• Katodritou E, Verrou E, Gastari V et al. Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence outcome? Leuk. Res.32(7), 1153–1156 (2008).
   PubMed Web of Science ®Google Scholar
• Musto P, Rossini F, Gay F et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer109(11), 2285–2290 (2007).
   PubMed Web of Science ®Google Scholar
• Chan SM, George T, Cherry AM, Medeiros BC. Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report. Cases J.2(1), 121 (2009).
   PubMedGoogle Scholar
• Al-Nawakil C, Tamburini J, Bardet V et al. Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy. Leuk. Lymphoma49(10), 2012–2014 (2008).
   PubMed Web of Science ®Google Scholar
• Musto P, Valentini C, D’Auria F et al. Bortezomib-containing combinations as front-line therapy in primary plasma cell leukemia: a retrospective study from GIMEMA multiple myeloma and acute leukemia working parties. Presented at: European Hematology Association Annual Meeting. Barcelona, Spain, 9–13 June 2010.
   Google Scholar
• Johnston RE, Abdalla SH. Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukemia. Leuk. Lymphoma43(2), 351–354 (2002).
   PubMed Web of Science ®Google Scholar
• Petrucci MT, Martini V, Levi A et al. Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center. Leuk. Lymphoma48(1), 180–182 (2007).
   PubMed Web of Science ®Google Scholar
• Musto P, Pietrantuono G, Guariglia R et al. Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia. Leuk. Res.32(10), 1637–1638 (2008).
   PubMed Web of Science ®Google Scholar
• Benson DM Jr, Smith MK. Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia. Leuk. Lymphoma48(7), 1423–1425 (2007).
   PubMed Web of Science ®Google Scholar
• Musto P, D’Auria F, Petrucci MT et al. Lenalidomide plus low dose dexamethasone as first line therapy in patients with primary plasma cell leukemia: planned interim analysis of a pilot study from the GIMEMA-Italian Myeloma Network. Presented at: European Hematology Association Annual Meeting. Barcelona, Spain, 9–13 June 2010.
   Google Scholar
• Drake MB, Iacobelli S, van Biezen A et al. Primary plasma cell leukemia and autologous stem cell transplantation. Haematologica95(5), 804–809 (2010).
   PubMed Web of Science ®Google Scholar
• Gertz MA and Buadi FK. Plasma cell leukemia. Haematologica95(5), 705–707 (2010).
   PubMedGoogle Scholar
• Mahindra A, Vesole D, Kalycio ME et al. Autologous hematopoietic stem cell transplantation (HCT) is a safe and effective treatment for primary plasma cell leukemia: the CIBMTR experience. Presented at: American Society of Hematology 51st Annual Meeting. New Orleans, LA, USA, 5–8 December 2009.
   Google Scholar
• Pagano L, Valentini CG, De Stefano V et al. Primary plasma cell leukemia: results of a retrospective Italian multicentric survey. Presented at: American Society of Hematology 51st Annual Meeting. New Orleans, LA, USA, 5–8 December 2009.
   Google Scholar